Hip fracture patients at heart risk may benefit from dual blood thinners

NCT ID NCT07228663

Not yet recruiting Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a combination of two blood thinners (rivaroxaban and aspirin) can prevent heart attacks and blood clots in patients who had a hip fracture surgery and also suffered a heart injury. About 100 adults aged 45 and older will be randomly assigned to either the combo for 90 days or standard clot-prevention treatment for 30 days. The main goal is to see if a larger trial is possible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rivaroxaban and aspirin
What this could lead to: If this pilot succeeds, it could lead to a larger trial testing whether a combination of blood thinners can prevent heart attacks and blood clots after hip fracture surgery.
What could go wrong: This is a small pilot study (100 people) testing feasibility, not effectiveness. The combination therapy also carries a risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hip fracture venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR PREVENTION HIP FRACTURE SURGERY VENOUS THROMBOEMBOLISM (VTE)

Contacts and locations

Locations

Humanitas Research Hospital

Milan, Italy
Juravinski Hospital

Hamilton, Ontario, L8V 1C3, Canada
St.Joseph's Healthcare Hamilton

Hamilton, Ontario, L8N 4A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.